Skip to main content
Fig. 6 | BMC Gastroenterology

Fig. 6

From: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis

Fig. 6

In vivo effect of MS275 on malignant ascites formation, tumor growth and mice survival. Compared with control group, less abdominal bulge (A) and parietal or visceral peritoneum carcinoma burden indicated with red arrows (D) were observed in MS275 treatment group. The body weight (B), the volume of ascites (C) at 24 h following the final treatment. Survival of mice after S180 cell inoculation into peritoneal cavity (n = 10) (E). **, P < 0.01 versus control group

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us